ERD

IMI2-2017-13-01 Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches

(1)

IMI2-2017-13-02 Genome-Environment Interactions in Inflammatory Skin Disease

(1)

IMI2-2017-13-03 The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use

(1)

IMI2-2017-13-04 Mitochondrial Dysfunction in Neurodegeneration

(1)

IMI2-2017-13-05 Support and coordination action for the projects of the Neurodegeneration area of the Innovative Medicines Initiative

(1)

IMI2-2017-13-06 A sustainable European induced pluripotent stem cell platform

(1)

IMI2-2017-13-07 Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice

(1)

IMI2-2017-13-08 Human Tumour Microenvironment Immunoprofiling

(1)

IMI2-2017-13-09 ConcePTION – Continuum of Evidence from Pregnancy Exposures, Reproductive Toxicology and Breastfeeding to Improve Outcomes Now

(1)

IMI2-2017-13-10 Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system

(1)

IMI2-2017-13-11 Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease

(1)

IMI2-2017-13-14 Pilot programme on a Clinical Compound Bank for Repurposing: Neurodegenerative diseases

(1)

IMI2-2017-13-15 Pilot programme on a Clinical Compound Bank for Repurposing: Rare/orphan diseases

(1)